BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,927
Mkt Cap
$2.35B
Volume
3,356.00
52W High
$11.31
52W Low
$6.00
PE Ratio
7.80
BCRX Fundamentals
Price
$9.38
Prev Close
$9.52
Open
$9.54
50D MA
$7.93
Beta
0.91
Avg. Volume
6.83M
EPS (Annual)
$1.21
P/B
-16.77
Rev/Employee
$2.01M
$1,907.31
Loading...
Loading...
News
all
press releases
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...
MarketBeat·9d ago
News Placeholder
Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today
Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week.
Stocktwits·9d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...
MarketBeat·9d ago
News Placeholder
BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak
Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.
Stocktwits·9d ago
News Placeholder
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 150,000 Shares of Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the...
MarketBeat·14d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an...
MarketBeat·15d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 13.8% - Should You Buy...
MarketBeat·17d ago
News Placeholder
Top Biotech Stocks To Keep An Eye On - March 16th
Danaher, Vertex Pharmaceuticals, Moderna, BioCryst Pharmaceuticals, ImmunityBio, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...
MarketBeat·17d ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.